Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock Has Consensus Target Price of $32.64

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned an average rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, nine have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $32.64.

Several research firms recently weighed in on BCAX. Wedbush raised their price objective on Bicara Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research note on Thursday, September 10th. BTIG Research boosted their target price on Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. HSBC cut shares of Bicara Therapeutics to an “equal weight” rating in a report on Tuesday, September 22nd. Finally, Morgan Stanley raised their price target on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $17.50 on Wednesday. The business has a fifty day moving average price of $22.59 and a two-hundred day moving average price of $23.20. Bicara Therapeutics has a fifty-two week low of $13.70 and a fifty-two week high of $30.99. The stock has a market capitalization of $1.16 billion, a PE ratio of -5.65 and a beta of -0.70.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.82). As a group, sell-side analysts expect that Bicara Therapeutics will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Claire Mazumdar sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the completion of the transaction, the chief executive officer directly owned 362,152 shares in the company, valued at $10,133,012.96. This represents a 2.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 18,750 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00. Following the completion of the transaction, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at approximately $5,082,315.18. The trade was a 9.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 58,750 shares of company stock worth $1,554,800 in the last three months. 13.80% of the stock is owned by corporate insiders.

Institutional Trading of Bicara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd increased its holdings in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after purchasing an additional 4,585 shares in the last quarter. Arizona State Retirement System bought a new position in Bicara Therapeutics in the second quarter valued at about $241,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Bicara Therapeutics during the second quarter valued at about $272,000. Letko Brosseau & Associates Inc. acquired a new stake in shares of Bicara Therapeutics during the fourth quarter valued at about $188,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Bicara Therapeutics during the second quarter valued at about $407,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc (NASDAQ: BCAX) is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to address both cancer cells and the tumor microenvironment, which can suppress immune responses and limit the effectiveness of existing treatments.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. It is an investigational bifunctional fusion protein designed to target the epidermal growth factor receptor (EGFR) on tumor cells while blocking transforming growth factor beta (TGF-β), a signaling pathway associated with tumor growth and immune suppression.